12:25 PM EDT, 08/11/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We slash our target to $11 from $22, a 5.3x multiple of our 2025 sales estimate, a discount to historical levels due to GLP-1 risks. We widen our 2025 net loss forecast to -$2.23 from-$1.44 and 2026's to -$0.86 from -$0.65. TNDM reported Q2 EPS of -$0.48, flat with Q2 2024, but missing the S&P Capital IQ consensus estimate by $0.08. Sales of $240.7M were up 8% Y/Y; however, profitability was more challenging with adjusted EBITDA of -$1.8 million (-1% of sales), compared to -$1.9 million (also -1% of sales) Y/Y. TNDM's guidance for 2025 suggests ongoing profitability challenges, as adjusted EBITDA margin is being lowered from "approximately 3%" to "approximately -5%" of sales for 2025, which now includes an -8 percentage point impact for an acquired in-process research and development charge. We think international sales will continue to grow faster than U.S., though we anticipate a $10 million headwind in 2025 associated with TNDM's preparation for direct commercial operations in select countries.